We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZH
12001
Zhihu
ZH
$272M
$38K ﹤0.01%
3,528
-13,152
-79% -$141K
ATYR
12002
CALL
aTyr Pharma
ATYR
$54.8M
$38K ﹤0.01%
13,500
-13,800
-51% -$49.9K
SHCR
12003
CALL
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
$38K ﹤0.01%
24,300
-7,300
-23% -$17.9K
SHPW
12004
CALL
DELISTED
Shapeways Holdings, Inc. Common Stock
SHPW
$38K ﹤0.01%
4,113
-3,325
-45% -$46.6K
KLR
12005
CALL
DELISTED
Kaleyra, Inc.
KLR
$38K ﹤0.01%
5,343
-6,514
-55% -$95.6K
PRTK
12006
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$38K ﹤0.01%
+19,600
New +$42.8K
STCN
12007
CALL
DELISTED
Steel Connect, Inc. Common Stock
STCN
$38K ﹤0.01%
3,075
+321
+12% +$3.81K
OBSV
12008
PUT
DELISTED
ObsEva SA Ordinary Shares
OBSV
$38K ﹤0.01%
23,800
-5,400
-18% -$8.91K
KLAQW
12009
DELISTED
KL Acquisition Corp Warrant
KLAQW
$38K ﹤0.01%
251,017
-274,800
-52% -$49.8K
ZY
12010
PUT
DELISTED
Zymergen Inc. Common Stock
ZY
$38K ﹤0.01%
30,600
-12,700
-29% -$21.3K
BKYI
12011
CALL
BIO-key International
BKYI
$3.46M
$37K ﹤0.01%
116
-1
-0.9% -$355
PRQR icon
12012
CALL
ProQR Therapeutics
PRQR
$271M
$37K ﹤0.01%
47,200
+16,200
+52% +$12.1K
TLSA icon
12013
Tiziana Life Sciences
TLSA
$145M
$37K ﹤0.01%
49,535
+35,562
+255% +$30.6K
NAGE
12014
PUT
Niagen Bioscience
NAGE
$239M
$37K ﹤0.01%
22,100
-28,600
-56% -$55.9K
CMRX
12015
CALL
DELISTED
Chimerix, Inc.
CMRX
$37K ﹤0.01%
18,000
-162,500
-90% -$522K
CSLMW
12016
DELISTED
CSLM Acquisition Corp. Warrant
CSLMW
$37K ﹤0.01%
437,500
SCPX
12017
PUT
DELISTED
Scorpius Holdings, Inc.
SCPX
$37K ﹤0.01%
4
IMV
12018
DELISTED
IMV Inc. Common Shares
IMV
$37K ﹤0.01%
5,661
+4,200
+287% +$43.5K
STON
12019
CALL
DELISTED
StoneMor Inc.
STON
$37K ﹤0.01%
+10,800
New +$30.7K
SMED
12020
CALL
DELISTED
Sharps Compliance Corp
SMED
$37K ﹤0.01%
12,800
-700
-5% -$2.92K
CIK
12021
Credit Suisse Asset Management Income Fund
CIK
$134M
$36K ﹤0.01%
13,083
+586
+5% +$1.66K
DMAC icon
12022
DiaMedica Therapeutics
DMAC
$360M
$36K ﹤0.01%
18,012
-20,220
-53% -$47.2K
FLUX icon
12023
PUT
Flux Power
FLUX
$12.7M
$36K ﹤0.01%
15,000
-16,200
-52% -$40K
GLBS icon
12024
PUT
Globus Maritime Ltd
GLBS
$78.6M
$36K ﹤0.01%
20,500
-200
-1% -$428
LIQT icon
12025
LiqTech
LIQT
$18.5M
$36K ﹤0.01%
+9,889
New +$84.9K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.